X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SAB Biotherapeutics lead product candidate SAB-142, which is an anti-thymocyte globulin. Currently being evaluated in the early stage trial studies for the treatment of type 1 diabetes.
Lead Product(s): SAB-142
Therapeutic Area: Endocrinology Product Name: SAB-142
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
The partnership aims to evaluate SAB-176, a fully human polyclonal antibodies targeting influenza from Transchromosomic (Tc) Bovine, being investigated for use as a pre- and post-exposure prophylactic treatment for influenza type A and type B.
Lead Product(s): SAB-176
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-176
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Naval Medical Research Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 25, 2024
Details:
SAB-142 is a CD2/CD3/CD4/CD8/CD154 Binder antibody drug, which is being investigated for the management of Type 1 Diabetes, as an intravenous infusion.
Lead Product(s): SAB-142
Therapeutic Area: Endocrinology Product Name: SAB-142
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
The financing will be used to fund the development of the company’s lead research program, SAB-142, a fully-human alternative to rabbit anti-thymocyte globulin and a potential disease modifying treatment for type 1 diabetes (T1D).
Lead Product(s): SAB-142
Therapeutic Area: Endocrinology Product Name: SAB-142
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sessa Capital
Deal Size: $67.1 million Upfront Cash: Undisclosed
Deal Type: Financing November 14, 2023
Details:
SAB-142 is the first fully-human anti-thymocyte hpAB therapeutic currently being developed for delaying the progression and onset of type 1 diabetes, among other autoimmune indications.
Lead Product(s): SAB-142
Therapeutic Area: Endocrinology Product Name: SAB-142
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
SAB will use the funds to clinically advance SAB-142, a fully-human alternative to rabbit anti-thymocyte globulin (rATG), its lead therapeutic candidate for type 1 diabetes (T1D).
Lead Product(s): SAB-142
Therapeutic Area: Endocrinology Product Name: SAB-142
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 02, 2023
Details:
SAB-185 is a fully human polyclonal antibody therapeutic, represents a highly-differentiated treatment option that provides a highly-specific match against the complexity, diversity, and the mutations SARS-CoV-2 presents.
Lead Product(s): SAB-185
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-185
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody therapeutic intended to prevent or reduce severe outcomes of Type A and Type B influenza infection.
Lead Product(s): SAB-176
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-176
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody therapeutic intended to prevent or reduce severe outcomes of Type A and Type B influenza infection.
Lead Product(s): SAB-176
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-176
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2023
Details:
SAB-185, a fully human polyclonal antibody therapeutic, represents a highly-differentiated treatment option that provides a highly-specific match against the complexity, diversity, and the mutations SARS-CoV-2 presents.
Lead Product(s): Human Polyclonal Antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: SAB-185
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: $16.8 million Upfront Cash: Undisclosed
Deal Type: Termination January 18, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
